This summer, students and professionals passionate about pharmaceutical innovation have a unique opportunity to gain hands-on experience in modern...

Big news from the Leiden Bio Science Park community: VitroScan has been awarded a ~€200K grant as part of the Medical:Forge Leipzig accelerator....

Leiden Bio Science Park welcomed Taiwan’s National Science and Technology Council on April 17th, promoting international collaboration in healthcare innovation, AI, and data-driven science. The visit featured expert presentations and strengthened ties between two leading life sciences ecosystems.

Leiden University researchers have developed the first-ever ‘dengue-on-a-chip’ model, using organ-on-a-chip technology to simulate the human body’s response to dengue infection, particularly focusing on hemorrhagic shock. This innovative tool offers a more ethical and cost-effective alternative to animal testing, aiding in the study of disease progression and the development of targeted treatments for the growing global health threat posed by dengue.

A study from Leiden University reveals that daily probiotic intake can help alleviate negative emotions like anxiety, stress, and fatigue, with participants reporting mood improvements after two weeks of consuming Lactobacillus and Bifidobacterium strains.

To help address the growing need for well-trained production personnel in the Life Sciences industry, Talentmark and Biotech Training Facility (BTF)...

On April 8, 2025, six academics from Leiden University were officially appointed as Medical Delta Professors, marking a significant milestone in interdisciplinary collaboration aimed at advancing sustainable healthcare solutions. The newly appointed professors bring diverse expertise from fields such as architecture, neuropsychology, epidemiology, and design, all contributing to innovations at the intersection of technology and healthcare.

From 6–9 May 2025, the Netherlands Embassy in Seoul, in collaboration with the Netherlands Enterprise Agency (RVO), is organising a trade mission to...

Leyden Laboratories B.V. has unveiled promising results from its study on intranasal antibody therapy, CR9114, which demonstrates broad-spectrum protection against influenza viruses, including A, B, C, and D strains. The research highlights the benefits of delivering antibodies directly to the nasal mucosa, offering a novel, low-dose approach to combating respiratory infections with a unique Fc-independent mechanism of action.